Send me a link:

*Text messaging rates may apply.

 Dow Down0.42% Nasdaq Down0.05%

More On B8F.DE



News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


Biofrontera AG (B8F.DE)

2.68 0.00(0.00%) 7:17AM EDT
ProfileGet Profile for:
Biofrontera AG
Hemmelrather Weg 201
Leverkusen, 51377
Germany - Map
Phone: 49 214 87 63 20
Fax: 49 214 87 63 290

Index Membership:N/A
Full Time Employees:39

Business Summary 

Biofrontera AG, a biopharmaceutical company, is engaged in the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy; and Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a specific serotonin receptor antagonist that is in Phase I clinical trial for migraine prophylaxis. In addition, it focuses on developing Ameluz for other superficial cancer and warts. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Biofrontera AG

Key Executives 
Prof. Hermann L Ph.D., 58
Co-Founder, Chairman of Management Board and Chief Exec. Officer
Mr. Thomas Schaffer ,
Chief Financial Officer and Member of Management Board
Mr. Fabian Esser Ph.D.,
Head of Marketing & Sales
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in EUR.